158 related articles for article (PubMed ID: 15809729)
1. Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Int J Oncol; 2005 May; 26(5):1363-8. PubMed ID: 15809729
[TBL] [Abstract][Full Text] [Related]
2. Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions.
Di Carlo A; Mariano A; Terracciano D; Mazzarella C; Galzerano S; Cicalese M; Cecere C; Macchia V
Oncol Rep; 2007 Aug; 18(2):425-31. PubMed ID: 17611666
[TBL] [Abstract][Full Text] [Related]
3. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer.
Hrabec E; Strek M; Nowak D; Hrabec Z
Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010
[TBL] [Abstract][Full Text] [Related]
4. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
5. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
[TBL] [Abstract][Full Text] [Related]
6. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
7. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
8. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma.
Di Carlo A
Oncol Rep; 2012 Sep; 28(3):1051-6. PubMed ID: 22711190
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer.
Park KJ; Hwang SC; Sheen SS; Oh YJ; Han JH; Lee KB
Respiration; 2005; 72(2):166-75. PubMed ID: 15824527
[TBL] [Abstract][Full Text] [Related]
11. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis.
Hrabec E; Strek M; Nowak D; Greger J; Suwalski M; Hrabec Z
J Cancer Res Clin Oncol; 2002 Apr; 128(4):197-204. PubMed ID: 11935310
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
13. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
van Hensbergen Y; Broxterman HJ; Hanemaaijer R; Jorna AS; van Lent NA; Verheul HM; Pinedo HM; Hoekman K
Clin Cancer Res; 2002 Dec; 8(12):3747-54. PubMed ID: 12473585
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.
Somiari SB; Shriver CD; Heckman C; Olsen C; Hu H; Jordan R; Arciero C; Russell S; Garguilo G; Hooke J; Somiari RI
Cancer Lett; 2006 Feb; 233(1):98-107. PubMed ID: 16473671
[TBL] [Abstract][Full Text] [Related]
15. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
17. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
Wang Y; Fang S; Wei L; Wang R; Jin X; Wen D; Li Y; Guo W; Wang N; Zhang J
Lung Cancer; 2005 Aug; 49(2):155-61. PubMed ID: 15949868
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.
Mroczko B; Kozłowski M; Groblewska M; Łukaszewicz M; Nikliński J; Jelski W; Laudański J; Chyczewski L; Szmitkowski M
Clin Chim Acta; 2008 Mar; 389(1-2):61-6. PubMed ID: 18155162
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of circulating matrix metalloproteinase-9 in non-small cell lung cancer patients.
Kaya A; Gülbay BE; Gürkan OU; Celik G; Savaş H; Savaş I
Tuberk Toraks; 2003; 51(4):380-4. PubMed ID: 15143385
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]